Jazz Pharmaceuticals Plc (JAZZ)
244.54
-6.56
(-2.61%)
USD |
NASDAQ |
Aug 28, 16:00
244.58
+0.04
(+0.02%)
After-Hours: 20:00
Jazz Pharmaceuticals Cash from Operations (Quarterly) : 415.70M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 415.70M |
| March 31, 2026 | 408.20M |
| December 31, 2025 | 362.52M |
| September 30, 2025 | 474.62M |
| June 30, 2025 | 88.86M |
| March 31, 2025 | 429.78M |
| December 31, 2024 | 398.58M |
| September 30, 2024 | 398.75M |
| June 30, 2024 | 331.35M |
| March 31, 2024 | 267.23M |
| December 31, 2023 | 167.34M |
| September 30, 2023 | 307.20M |
| June 30, 2023 | 296.76M |
| March 31, 2023 | 320.71M |
| December 31, 2022 | 341.97M |
| September 30, 2022 | 417.99M |
| June 30, 2022 | 303.04M |
| March 31, 2022 | 208.98M |
| December 31, 2021 | 177.76M |
| September 30, 2021 | 274.06M |
| June 30, 2021 | 41.70M |
| March 31, 2021 | 285.00M |
| December 31, 2020 | 186.27M |
| September 30, 2020 | 257.89M |
| June 30, 2020 | 182.52M |
| Date | Value |
|---|---|
| March 31, 2020 | 272.97M |
| December 31, 2019 | 87.80M |
| September 30, 2019 | 337.50M |
| June 30, 2019 | 148.85M |
| March 31, 2019 | 202.25M |
| December 31, 2018 | 224.35M |
| September 30, 2018 | 220.58M |
| June 30, 2018 | 185.22M |
| March 31, 2018 | 162.36M |
| December 31, 2017 | 204.56M |
| September 30, 2017 | 188.90M |
| June 30, 2017 | 135.09M |
| March 31, 2017 | 164.54M |
| December 31, 2016 | 178.84M |
| September 30, 2016 | 133.03M |
| June 30, 2016 | 127.01M |
| March 31, 2016 | 151.65M |
| December 31, 2015 | 119.74M |
| September 30, 2015 | 175.08M |
| June 30, 2015 | 140.57M |
| March 31, 2015 | 96.56M |
| December 31, 2014 | 132.42M |
| September 30, 2014 | 129.70M |
| June 30, 2014 | 74.92M |
| March 31, 2014 | 68.72M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Avadel Pharmaceuticals Plc | 23.27M |
| Perrigo Co. Plc | 82.60M |
| GH Research Plc | -14.94M |
| Cosmo NV | -- |
| Axsome Therapeutics, Inc. | -32.95M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 354.90M |
| Cash from Financing (Quarterly) | -994.50M |
| Free Cash Flow | 1.508B |
| Free Cash Flow Per Share (Quarterly) | 5.729 |
| Free Cash Flow to Equity (Quarterly) | 1.405B |
| Free Cash Flow to Firm (Quarterly) | 454.65M |
| Free Cash Flow Yield | 9.47% |